Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes
A European Medicines Agency (EMA) panel has backed Eli Lilly’s Foundayo (orforglipron) for approval, helping the drugmaker close the gap…
16 Oct 2026
OrbiMed raises $3bn to back global life science players
Global healthcare investment giant OrbiMed has raised $3bn for two new private equity funds to support the growth of companies across the European, US and Asian life sciences sectors. This…
16 Oct 2026
AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership
AstraZeneca has inked a billion-dollar artificial intelligence (AI)-powered drug discovery partnership and licensing deal with insitro, to identify novel targets and therapies for a range of cardiometabolic diseases. Through this…
16 Oct 2026
Acta Pharmaceuticals raises $24m for Alzheimer’s therapies
Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of Alzheimer’s disease (AD), including the clinical progression of its lead…
16 Oct 2026
RevMed’s pancreatic cancer drug inches closer to EU approval after panel’s backing
A European Medicines Agency (EMA) panel has recommended approval of Revolution Medicines’ Rasonque (daraxonrasib) for certain pancreatic cancer patients, marking a likely new market entry in Europe for a drug…
16 Oct 2026
Transcripta Bio, Mayo Clinic join force on ALS therapies
Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for amyotrophic lateral sclerosis (ALS). The initiative centres on…
15 Oct 2026
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
Gilead Sciences and Vir Biotechnology have deepened their ties by inking a second deal, which will see the pair join forces to discover and engineer novel T-cell engager (TCE) therapies…